Inventory Huddle #4
April 24, 2020

During the call, please submit questions via the WebEx window or to solutions@amerisourcebergen.com.

Please dial-in to hear audio  1-866-659-9166   Passcode: 242 600 94 #
Today’s Speakers

Alexis Rose
VP, Strategic Accounts

Heather Zenk, RPh, PharmD
Senior Vice President, Replenishment & Manufacturer Operations

Sue Mashni
VP/Chief Pharmacy Officer, Mt. Sinai Health System

Please dial-in to hear audio 1-866-659-9166  Passcode: 242 600 94 #
Spotlight: Welcome, Sue Mashni

Sue Mashni
VP/Chief Pharmacy Officer
Mt. Sinai Health System
New York

Please dial-in to hear audio 1-866-659-9166   Passcode: 242 600 94 #
Hospital Pharmacy Insights: Sue Mashni  
Mt. Sinai Health System

- Sourcing, Staffing, Tents, and Partnerships (and using PAPER!)
- Clinical Challenges: The Daily Next Best Thing
- Leadership: Managing Expectations
- New Voice to ASHP, FDA, Governor’s Office, Pence’s office
- Preparation of FEMA Reports
- Nest Steps: Things we “should have done and will do now”
  - Standardization (Crash Cart Trays, Dispensing Strategies)
  - Virtualization
  - Optimization of Epic Inventory and “Burn Rate”

Please dial-in to hear audio 1-866-659-9166    Passcode: 242 600 94 #
Updated CDC Guidance:
Persons at Risk for Infection with SARS-CoV-2 (COVID-19)

Pre-Exposure Prophylaxis
Treatment Guidelines Panel does not recommend the use of any agents for SARS-CoV-2 pre-exposure prophylaxis (PrEP) outside the setting of a clinical trial.

At present, no agent given before an exposure is known to be effective in preventing SARS-CoV-2 infection. Clinical trials using hydroxychloroquine, chloroquine, or HIV protease inhibitors as PrEP are in development or underway.

Post-Exposure Prophylaxis
Treatment Guidelines Panel does not recommend the use of any agents for COVID-19 post-exposure prophylaxis (PEP) outside the setting of a clinical trial.

At present, no agent is known to be effective for preventing SARS-CoV-2 infection after an exposure. Potential options for PEP currently under investigation in clinical trials include hydroxychloroquine, chloroquine, or lopinavir/ritonavir.

- There is insufficient clinical data to recommend either for or against using chloroquine or hydroxychloroquine for the treatment of COVID-19.
- If chloroquine or hydroxychloroquine is used, clinicians should monitor the patient for adverse effects, especially prolonged QTc interval.
- There is insufficient clinical data to recommend either for or against using the investigational antiviral drug remdesivir for the treatment of COVID-19.
- Remdesivir as a treatment for COVID-19 is currently being investigated in clinical trials and is also available through expanded access and compassionate use mechanisms for certain patient populations.
- Except in the context of a clinical trial, the COVID-19 Treatment Guidelines Panel recommends against the use of the following drugs for the treatment of COVID-19:
  - The combination of hydroxychloroquine plus azithromycin because of potential for toxicities.
  - Lopinavir/ritonavir or other HIV protease inhibitors because of unfavorable pharmacodynamics and negative clinical trial data.
Hydroxychloroquine (HCQ)

- Continuing to partner with multiple manufacturers and the SNS for HCQ distribution
- Any product AmerisourceBergen receives from the SNS is directed to specific locations by FEMA and the White House
  - For any product donated to AmerisourceBergen, we will donate our distribution services and forgo all fees
  - Product obtained through the Strategic National Stockpile (SNS) should not be returned to AmerisourceBergen.
- For customers wanting to decrease or suspend shipments of HCQ from the SNS, please contact your AmerisourceBergen representative.
Inventory Update

• Generally, inventory demand is beginning to stabilize as the regional COVID-19 peaks begin to subside
  • Keeping a watchful eye on 90-day refill cycle

• Challenges Remain
  • Ventilator and intubation drugs
  • Sedatives
  • Experimental COVID-19 therapies
    • Hydroxychloroquine, Remdesivir®, Kaletra®, Actemra®
  • Azithromycin
  • Injectable narcotics
  • Insulin
  • Metered Dose Inhalers (MDIs)
We are united in our responsibility to create healthier futures.
Pulse Survey

In order to make these Inventory Huddles as valuable as possible and ensure AmerisourceBergen is supporting you to the best of our ability in these challenging times, we will be sending all participants at today’s session a short pulse survey.

Thank you in advance for your participation and feedback!!
Please submit questions directly in the WebEx window